MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases.

Article Details

Citation
Copy to clipboard

Dudich E

MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases.

Curr Opin Mol Ther. 2007 Dec;9(6):603-10.

PubMed ID
18041671 [ View in PubMed
]
Abstract

Merrimack Pharmaceuticals Inc (previously Atlantic Biopharmaceuticals) is developing MM-093 (formerly ABI-001), an injectable formulation of a recombinant human alpha-fetoprotein, for the potential treatment of myasthenia gravis, multiple sclerosis, rheumatoid arthritis, autoimmune uveitis and psoriasis. MM-093 is currently undergoing phase II clinical trials for rheumatoid arthritis, psoriasis and autoimmune uveitis.

DrugBank Data that Cites this Article

Drugs